MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.

Phase 1

Conditions: Patients treated with IV moderately emetogenic chemotherapy and at high risk of chemotherapy induced nausea and vomiting (CINV)
Therapeutic area: Diseases [C] - Cancer [C04]

Registration Number: EUCTR2019-004686-41-CZ

Lead Sponsor: Helsinn Healthcare SA

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 530

Inclusion Criteria

-Adult patients aged =18 years
-Patients with a risk score of = 13 as calculated by the algorithm (specified in protocol)
-Signed Informed consent
-Both sexes
-Patients with diagnosis of any cancer scheduled and intended to be treated for three consecutive cycles with a single dose of any IV MEC regimen, per cycle, including adjuvant or neo-adjuvant chemotherapy
-Patients with ECOG performance status 0, 1 or 2
-Use of Standard of Care defined as a 5-HT3 RA + Dexamethasone (or equivalent corticosteroid) based-regimen on day 1 of chemotherapy for CINV prevention
-Naïve and non- naïve to chemotherapy
-Able to comply with study requirements

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 130

Exclusion Criteria

-Patients receiving highly emetogenic chemotherapy (including anthracycline+cyclophosphamide-based chemotherapy)
-Patients receiving oral moderately emetogenic chemotherapy drugs
-Patients receiving opioids within 2 weeks prior to trial enrollment (longer use allowed)
-Use of olanzapine as prophylaxis of CINV
-Patients scheduled to receive radiotherapy concurrently with chemotherapy
-Any illness or condition that, in the opinion of the physician, may confound the results of the study or pose unwarranted risks in administering the investigational product to the patient.
-Patients with mechanical risk factors for nausea (i.e. intestinal obstruction)
-Patients with liver disease (as nausea is a common presenting symptom)
-Patients with metabolic risk factors for nausea (i.e. electrolyte imbalances causing nausea/vomiting)
-Chronic treatment with steroids (with the exception of inhaled or topical steroids)
-Pregnancy and/or breast-feeding women
-Use of Standard of Care including an NK-1 RA-based regimen to prevent CINV